Orion Oyj (OTCMKTS:ORINY) Stock Price Down 0.9% – Time to Sell?

Orion Oyj (OTCMKTS:ORINY)’s share price was down 0.9% during mid-day trading on Tuesday . The stock traded as low as $23.36 and last traded at $23.36. Approximately 151 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 488 shares. The stock had previously closed at $23.57.

Orion Oyj Price Performance

The firm has a fifty day simple moving average of $25.46 and a 200-day simple moving average of $23.67. The company has a market capitalization of $6.59 billion, a P/E ratio of 18.54 and a beta of 0.22. The company has a quick ratio of 1.29, a current ratio of 2.39 and a debt-to-equity ratio of 0.31.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share (EPS) for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The company had revenue of $517.97 million during the quarter. On average, equities research analysts expect that Orion Oyj will post 1.26 EPS for the current fiscal year.

Orion Oyj Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, November 7th. Stockholders of record on Wednesday, October 16th were given a $0.2405 dividend. The ex-dividend date was Wednesday, October 16th. Orion Oyj’s payout ratio is 26.98%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.